376 related articles for article (PubMed ID: 32585893)
1. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.
Marin JJG; Macias RIR; Monte MJ; Romero MR; Asensio M; Sanchez-Martin A; Cives-Losada C; Temprano AG; Espinosa-Escudero R; Reviejo M; Bohorquez LH; Briz O
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585893
[TBL] [Abstract][Full Text] [Related]
2. Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma.
Marin JJG; Perez-Silva L; Macias RIR; Asensio M; Peleteiro-Vigil A; Sanchez-Martin A; Cives-Losada C; Sanchon-Sanchez P; Sanchez De Blas B; Herraez E; Briz O; Lozano E
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751679
[TBL] [Abstract][Full Text] [Related]
3. Molecular bases of the poor response of liver cancer to chemotherapy.
Marin JJG; Briz O; Herraez E; Lozano E; Asensio M; Di Giacomo S; Romero MR; Osorio-Padilla LM; Santos-Llamas AI; Serrano MA; Armengol C; Efferth T; Macias RIR
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):182-192. PubMed ID: 29544679
[TBL] [Abstract][Full Text] [Related]
4. Cellular Mechanisms Accounting for the Refractoriness of Colorectal Carcinoma to Pharmacological Treatment.
Marin JJG; Macias RIR; Monte MJ; Herraez E; Peleteiro-Vigil A; Blas BS; Sanchon-Sanchez P; Temprano AG; Espinosa-Escudero RA; Lozano E; Briz O; Romero MR
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32933095
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to Chemotherapy in Gastric Cancer.
Marin JJ; Al-Abdulla R; Lozano E; Briz O; Bujanda L; Banales JM; Macias RI
Anticancer Agents Med Chem; 2016; 16(3):318-34. PubMed ID: 26234359
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib.
Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S
J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
8. Molecular Bases of Chemoresistance in Cholangiocarcinoma.
Marin JJG; Lozano E; Briz O; Al-Abdulla R; Serrano MA; Macias RIR
Curr Drug Targets; 2017; 18(8):889-900. PubMed ID: 25706108
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G
World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525
[TBL] [Abstract][Full Text] [Related]
10. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Mir N; Jayachandran A; Dhungel B; Shrestha R; Steel JC
Curr Cancer Drug Targets; 2017; 17(8):698-706. PubMed ID: 28460616
[TBL] [Abstract][Full Text] [Related]
12. Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.
Devan AR; Kumar AR; Nair B; Anto NP; Muraleedharan A; Mathew B; Kim H; Nath LR
Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358082
[TBL] [Abstract][Full Text] [Related]
13. Models for Understanding Resistance to Chemotherapy in Liver Cancer.
Marin JJG; Herraez E; Lozano E; Macias RIR; Briz O
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31671735
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma: Etiology and Current and Future Drugs.
Jindal A; Thadi A; Shailubhai K
J Clin Exp Hepatol; 2019; 9(2):221-232. PubMed ID: 31024205
[TBL] [Abstract][Full Text] [Related]
15. Molecular bases of liver cancer refractoriness to pharmacological treatment.
Marin JJ; Romero MR; Briz O
Curr Med Chem; 2010; 17(8):709-40. PubMed ID: 20088759
[TBL] [Abstract][Full Text] [Related]
16. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Fernando J; Malfettone A; Cepeda EB; Vilarrasa-Blasi R; Bertran E; Raimondi G; Fabra À; Alvarez-Barrientos A; Fernández-Salguero P; Fernández-Rodríguez CM; Giannelli G; Sancho P; Fabregat I
Int J Cancer; 2015 Feb; 136(4):E161-72. PubMed ID: 25053293
[TBL] [Abstract][Full Text] [Related]
17. Failure of Chemotherapy in Hepatocellular Carcinoma Due to Impaired and Dysregulated Primary Liver Drug Metabolizing Enzymes and Drug Transport Proteins: What to Do?
Ul-Islam S; Ahmed MB; Shehzad A; Ul-Islam M; Lee YS
Curr Drug Metab; 2018; 19(10):819-829. PubMed ID: 29807513
[TBL] [Abstract][Full Text] [Related]
18. Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds.
Vaquero J; Briz O; Herraez E; Muntané J; Marin JJ
Biochim Biophys Acta; 2013 Oct; 1833(10):2212-9. PubMed ID: 23680185
[TBL] [Abstract][Full Text] [Related]
19. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.
Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F
Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580
[TBL] [Abstract][Full Text] [Related]
20. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
